(NASDAQ: MGRX) INVESTOR PRESENTATION MAY 2025 1 SAFE HARBOUR AND FORWARD LOOKING STATEMENTS Forward-Looking Statements Certain statements made in this presentation contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward- looking statements represent Mangoceuticals, Inc.’s (the “Company’s”, “we” and “our”) current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward- looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to, our ability to obtain additional funding and generate revenues to support our operations; risks associated with our erectile dysfunction (ED) product which has not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that thecompounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may havegreater resources; our significant reliance on related party transactions; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, has majority voting control over the Company; risks related to the significant number of shares in the public float, our limited share volume, the effect of sales of a significant number of shares in the marketpalce, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering, the fact that we have generated only limited revenues to date; the continuing effect of COVID-19 on our planned operations, sales, and the market for our products; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; our ability to expand and grow our operations, and successfully market our planned; changes in, and our compliance with, rules and regulations affecting our operations, sales, and/or our products; shipping, production or manufacturing delays; our ability to obtain and increase sales; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; competition from existing competitors or new competitors or products that may emerge; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises; our ability to protect intellectual property rights; our ability to adequately support future growth; our ability to attract and retain key personnel to manage our business effectively;our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potentialrecessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. Market Information In this presentation, we may rely on and refer to information regarding the market for our products in general from third party studies, market research reports, and other publicly available information. Although we believe that this information is reliable, we have not commissioned any of such information, we information, and we have not independently verified any of it. Date of Information in Presentation All information in this presentation is as of May 5th, 2025 (unless otherwise stated). The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations. More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2023. These filings are available at www.sec.govand at our website at https://investors.mangorx.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. 2 BASED OUT OF DALLAS, TEXAS, USA CURRENTLY TRADING ON THE NASDAQ AT US $16M CLINICALLY PROVEN PORTFOLIO OF READY-FOR-MARKET PRODUCTS EXPANDING GLOBAL DISTRIBUTION CHANNELS, B2B AND B2C STRATEGICALLY TIMING THE HEALTH AND WELLNESS MEGA-TREND DIVERSIFIED PORTFOLIO OF PATENTS, FORMULATIONS, AND SCIENCE MANGOCEUTICALS AT A GLANCE Mangoceuticals, Inc. ( NASDAQ: MGRX ) (“ Mango ”) is a nutraceutical wellness company focused on developing and delivering a growing portfolio of men’s and women’s health and wellness products through a Direct to Consumer (DTC) platform. Portfolio of proprietary clinically proven nutraceutical formulations. Trades on the NASDAQ with a US $16M market cap. Mango is strategically timing the health and wellness mega-trend, and has a multi-prong business plan. Nutraceutical formulations, brands and delivery technologies. Biotech RX molecule development across core verticals. Digital Health and Wellness. Mango is focused on several core categories: Weight Management, Diabetes, Energy, and more. AS SEEN IN: 3 HOUSE OF BRANDS MENDYou Your Nutraceuticals One Platform. Multiple Products and Brands - Disrupting the Way Consumers Feel. 4 DISRUPTION BY BRAND Revenue: $59M+ Revenue: $1.88B+ Revenue: $250M+ Revenue: $500M+ 5 INVESTMENT HIGHLIGHTS Strategic Acquisitions Driving IP Expansion Acquired Smokeless Technology Corp. Gained exclusive stimulant/energy pouch IP portfolio Brings on Tim Corkum (former JUUL President) and other top-tier talent Disrupting Trillion Dollar Markets Stimulant/Energy Pouches – Healthy alternative to nicotine. Blood Sugar Management – $400B+ addressable problem Mood, Focus, and Metabolic Health supplements Rapid Revenue Growth Potential $44.5M projected annualized revenue for 2026 10x+ revenue scaling between 2025 and 2026 Strong gross margins (up to 50%) across core SKUs World-Class CPG & Pharma Leadership Fortune 150 Executives: Ex-JUUL, Philip Morris, GrubHub, Amber Beverage Group, OGI execs Led exits, scale-ups, and category-defining launches Clinically Proven, Patent-Protected Products Diabetinol: backed by 10+ years of clinical research MENDYou, THRLL, and Dermytol: proprietary formulations with clinical edge Natural ingredients, no prescription required Clear Capital Markets Pathway Trading on NASDAQ under ticker MGRX Significantly undervalued in comparison to peers trading at 3.0 - 7.0x EV/2026E revenue Positioned for institutional re-rating and scalability Capitalizing a once in a generation opportunity disrupting numerous multi-billion dollar opportunities 01 02 03 04 05 06 6 A nationwide movement to improve metabolic health, one pouch and one patent at a time. We believe everyone deserves access to effective and affordable wellness tools. MAHA is our call to action, a commitment to restore health, energy, and vitality across America. MAKE AMERICA HEALTHY AGAIN INITIATIVE Our Why: A National Health Crisis America faces an epidemic of lifestyle-driven conditions: Obesity Blood sugar disorders (Type 2 diabetes, prediabetes) Nicotine addiction Chronic fatigue and metabolic decline Millions lack affordable, accessible solutions that fit modern lifestyles. Our Timing: The Perfect Storm for Disruption The U.S. is ready for a high-growth, Nasdaq-listed nutraceutical platform to lead this shift. Mangoceuticals Inc. is positioned to deliver clean, clinically supported alternatives across underserved wellness categories. The convergence of rising public health urgency, mainstream supplement acceptance, and digital DTC acceleration makes this moment pivotal. Our Solution: Mangoceuticals' House of Brands Through innovative pouches, supplements, and functional health products, we offer: Diabetinol – clinically proven glucose and lipid support. THRLL – clean stimulant energy for focus & performance. MENDYou, Dermytol & more – targeting mood, skin, metabolism, and immunity. All products are vegan, non-GMO, and prescription-free. Robert F. Kennedy Jr. 7 $29.2B+ $77.6B+ Diabetes: The diabetes supplements market is projected to reach $29.2B by 2030, exhibiting a CAGR of 9.5%. 1 Pouches: The global pouch market is projected to reach approximately $77.6B by 2032, growing at a CAGR of 6.2%. 2 Weight Loss / Management: The global weight management market is projected to reach between $298.7B and $405.4B by 2030, with CAGRs ranging from 6.8% to 9.9%. 3 Nutraceuticals: The global nutraceuticals market is projected to reach approximately $620.3B by 2030, expanding at a CAGR of 5.8%. 4 Health and Wellness: The health and wellness market is projected to reach approximately $6.75T by 2030, with a compound annual growth rate (CAGR) of 5.2%. 5 MANGOCEUTICALS CORE MARKETS TAM $620.3B+ $405.4B+ $6.8T+ Total addressable markets in billions 2030 estimates Sources: 1 - Extapolate, 2 - Grand View Research, 3 - Grand View Research, 4 - Persistence Market Research, 5 - BioSpace 8 Introducing Diabetinol Diabetinol is a natural blood sugar management breakthrough. It's a clinically-proven, all-natural product that helps control blood glucose levels, reduces cholesterol, and supports healthy weight management. 9 DIABETES IS OUT OF CONTROL Always available Zero side effects Diabetinol's Competitive Edge Significant cost savings No prescription or blood work requirements Within the supplement category, Diabetinol's multiple clinical trials and precise formulation provide powerful competitive advantages More than 30M Americans have Type 2 Diabetes. 1 in 3 Americans are pre-diabetic. $400B annual costs impacting health and productivity. Current drugs are inaccessible due to high costs, prescriptions, and complexity. Given the massive market, room exists for numerous competitors, while our first-mover advantage – with proven efficacy – can make us an early market leader. The high cost of GLP-1 drugs like Ozempic has sidelined millions, making it frustrating to watch others lose weight with medications they can’t afford. The market is ready for effective, accessible alternatives. With the Kardashians and major influencers entering the blood sugar space, it’s clear the market is ripe. Metabolic health is now mainstream— and we offer a rare, clinically proven supplement that’s both affordable and accessible. 10 Diabetinol is an all-natural and vegan formula free from additives, colors, and GMOs—designed for those seeking accessible, clean health support. Diabetinol also works as an adjunct to medications like Metformin, helping patients achieve better blood sugar control when drugs alone aren’t enough. Our patented formula has undergone rigorous clinical trials, placing it among the top nutraceuticals for proven efficacy. Developed over 10+ years of research, Diabetinol uses citrus-based compounds to help regulate blood glucose naturally. SCIENTIFICALLY BACKED. CLINICALLY PROVEN. 11 Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP. Brings Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division. World Class Leadership Team Established Distribution Channels New Synergistic Product Offerings Greater Access to Capital Proprietary IP and Rare Ingredients Institutional Re-Rating and Value Creation Opportunity Revenue & Margin Acceleration ACQUISITION OF SMOKELESS TECHNOLOGY CORP. 12 13 With Smokeless Technology Corp., we are building and formulating a portfolio of better-for-you energy / stimulant pouches with and without nicotine. Our pouches are infused with disruptive and proprietary formulations that include natural and exotic super-ingredients strategically sourced and formulated by partner innovation labs. Our team brings together Research and Development and Commercialization experts from science, consumer packaged goods, nutraceuticals, pharmaceuticals, and big tobacco to create a world-class team THRLL offers a new generation of energy pouches—an innovative alternative to traditional nicotine products. With a bold vision to replace energy drinks and other caffeine-based boosters, THRLL delivers a cleaner, more convenient way to stay energized. REDEFINING THE STIMULANT POUCH MARKET ONE PRODUCT. LIMITLESS USE CASES. Precision energy to keep your swing sharp every hole, every round. Boost endurance and mental clarity—no shake or prep needed. Quick, crash-free energy to sharpen your game instantly. Stay sharp and productive from meeting 1 to inbox zero. Great for corporate gifting or productivity- boosting perks. Golf Fitness Sports Executives Corporate THRLL is just the beginning. As we scale, our strategy includes launching additional brands and formulations tailored to specific consumer demographics. From youth-focused nootropics to wellness-first pouches for aging populations, our platform is designed to diversify, adapt, and lead across emerging demand segments. 14 Najla Guthrie Co-founder and Director Garry Siskos CFO Will oversee public listing process Tim Corkum CEO Phillip Morris Executive and Former President of JUUL Dr. Prashant Khemariya Vice-President Regulatory Affairs and Licensing WORLD CLASS TEAM Dr. Mansour Alvi Advisor Amanda Hammer COO Eugene M. Johnston CFO Jacob Cohen Co-Founder and CEO 15 16 Adapt and optimize formulations for Rx-grade use Onboard President of Pouch Division, Tim Corkum, Phillip Morris Executive and Former President of JUUL, and core team Develop e-commerce infrastructure and Rx Pouch branding Mangocueticals Inc. (NASDAQ: MGRX) Acquisition of Smokeless Tech IP Expanded advisory board with global beverage and branding expertise Looking to sign partnerships for unique and novel ingredients Go-to-market pre- sale campaign Add seasoned executive advisor with extensive experience in consumer packaged goods Commencement of Clinical Claims Study DTC e-commerce and multi- channel marketing campaign launch of Pouch Rx division Added experienced industry advisor to strengthen strategic oversight Finalize formulation for 3 lead products (energy, mood, focus) Expand influencer campaigns and launch affiliate partnerships Sample production run of lead formulation METHODICAL AND PROFITABLE GROWTH OF MANGOCEUTICALS INC. Q2 2025 Q2 2025 Q2 2025 Q2 2025 Q3 2025 Q3 2025 Q3 2025 Q4 2025 Q4 2025 Q4 2025 Q4 2025 Q3 2025 Q1 2026 Q1 2026 CONSOLIDATED REVENUE FORECAST QUARTERLY REVENUE IN MILLIONS Q1 2026 Q2 2026 Q3 2026 Q4 2026 2025 $3 Million $4.1 Million $6 Million $10 Million $23.1 Million 2026 ANNUALIZED REVENUE 17 Mangoceuticals Inc. Diabetinol Smokeless Tech Corp. Q4 2025 $1.8 Million 2026 Significant value creation for shareholders on re-rate and expanded revenue generation through pouch division provides meaningful upside 18 ZYVA At a Glance VALUE CREATION ANALYSIS 2026E Revenue Mangoceuticals $23.1M Valuation Multiples EV / 2026E Revenue 4.0x 8.0x Illustrative Enterprise Value $92.4M $184.8M $18M Current Enterprise Value $18.5 PER SHARE $1.80 PER SHARE $9.2 PER SHARE 2.91 3.39 COMPARABLE COMPANY ANALYSIS EV/EBITDA (FWD) EV/Sales (FWD) Price/Sales (TTM) Enterprise Value Market Cap Company EV/Sales (TTM) EV/EBITDA (TTM) Turning Points Brands Novo Nordisk A/S (Ozempic) Abbott Laboratories Philip Morris International $1.01B $306.55B $231.09B $245.29B $1.22B $318.14B $237.78B $289.30B 2.80 7.62 5.46 6.47 6.13 7.20 7.89 5.62 7.64 11.08 12.03 20.43 16.54 13.00 15.39 21.53 19.28 5.33 LF*GO! Inc., Lemme and other private entities 19 20 Mangoceuticals is redefining nutraceutical quality with science-backed formulas. Diabetinol® has completed rigorous, peer- reviewed clinical trials showing significant improvements in blood glucose, lipid levels, and blood pressure. This scientific foundation sets it apart in a market saturated with unproven supplements. Mangoceuticals leads the new era of wellness by fusing evidence-based innovation with consumer-first design. With a diverse product line spanning diabetic support, stimulant pouches, and functional supplements, the company is meeting the needs of modern health-conscious consumers across North America. The Company has enhanced the strength of all of its brands since their respective acquisitions by: The Company's products generally fall into one of three categories: Supplements Clinically-proven products Diet, energy and other Clinically Validated Products Post-Acquisition Brand Optimization Market Leadership in Wellness 3 Core Product Categories DRIVING GROWTH WITH INNOVATION, SCIENCE & SCALE Expanded geographic sales force and brand coverage. Growth incentives for brand managers and sales representatives. Sophisticated management info systems. Brand packaging upgrades.